Laser vaccine adjuvant for cutaneous immunization

References

• Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine25(52), 8833–8842 (2007).
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med.7, 13 (2009).
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis.198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine26(26), 3197–3208 (2008).
   PubMed Web of Science ®Google Scholar
• Chen X, Kim P, Farinelli B et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One5(10), e13776 (2010).
   PubMed Web of Science ®Google Scholar
• Lofquist JM, Weimert NA, Hayney MS. Smallpox: a review of clinical disease and vaccination. Am. J. Health Syst. Pharm.60(8), 749–756 (2003).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med.351(22), 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med.351(22), 2295–2301 (2004).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis.10, 134 (2010).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis.191(2), 278–288 (2005).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Dekker JP III, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun.74(12), 6806–6810 (2006).
   PubMed Web of Science ®Google Scholar
• Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin. Infect. Dis.14(3), 697–707 (1992).
   PubMed Web of Science ®Google Scholar
• Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA254(22), 3203–3206 (1985).
   PubMed Web of Science ®Google Scholar
• Warrell MJ, Warrell DA, Suntharasamai P et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. Lancet2(8345), 301–304 (1983).
   PubMed Web of Science ®Google Scholar
• Barraclough KA, Wiggins KJ, Hawley CM et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am. J. Kidney Dis.54(1), 95–103 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Austin G, Chen RT et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine19(32), 4703–4709 (2001).
   PubMed Web of Science ®Google Scholar
• Frech SA, Dupont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet371(9629), 2019–2025 (2008).
   PubMed Web of Science ®Google Scholar
• Matriano JA, Cormier M, Johnson J et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res.19(1), 63–70 (2002).
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol.333, 369–393 (2009).
   PubMedGoogle Scholar
• Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin. Infect. Dis.50(10), 1331–1338 (2010).
   PubMed Web of Science ®Google Scholar
• Wack A, Rappuoli R. Vaccinology at the beginning of the 21st Century. Curr. Opin. Immunol.17(4), 411–418 (2005).
   PubMed Web of Science ®Google Scholar
• Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. J. Formos. Med. Assoc.109(1), 4–24 (2010).
   PubMed Web of Science ®Google Scholar
• Asa PB, Wilson RB, Garry RF. Antibodies to squalene in recipients of anthrax vaccine. Exp. Mol. Pathol.73(1), 19–27 (2002).
   PubMed Web of Science ®Google Scholar
• Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol.68(1), 55–64 (2000).
   PubMedGoogle Scholar
• Satoh M, Kuroda Y, Yoshida H et al. Induction of lupus autoantibodies by adjuvants. J. Autoimmun.21(1), 1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol.5(7), 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science316(5831), 1628–1632 (2007).
   PubMed Web of Science ®Google Scholar
• Gu M, Hine PM, James JW, Giri L, Nabors GS. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine25(3), 526–534 (2007).
   PubMed Web of Science ®Google Scholar
• Fransen F, Boog CJ, van Putten JP, van der LP. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect. Immun.75(12), 5939–5946 (2007).
   PubMed Web of Science ®Google Scholar
• Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun.71(5), 2498–2507 (2003).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30(1), 23–32 (2009).
   PubMed Web of Science ®Google Scholar
• Onikienko SB, Zemlyanoy AB, Margulis BA et al. Interactions of bacterial endotoxins and lipophilic xenobiotics with receptors associated with innate immunity. Donosologiya (St Petersburg)1, 32–54 (2006).
   Google Scholar
• Nishibu A, Ward BR, Jester JV, Ploegh HL, Boes M, Takashima A. Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli. J. Invest. Dermatol.126(4), 787–796 (2006).
   PubMed Web of Science ®Google Scholar
• Sangaletti S, Gioiosa L, Guiducci C et al. Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. J. Cell Sci.118(Pt 16), 3685–3694 (2005).
   PubMedGoogle Scholar
• Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med.206(13), 2925–2935 (2009).
   PubMedGoogle Scholar
• Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev.56(5), 559–579 (2004).
   PubMed Web of Science ®Google Scholar
• Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study. J. Control Release115(3), 344–353 (2006).
   PubMed Web of Science ®Google Scholar
• Zeira E, Manevitch A, Manevitch Z et al. Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. FASEB J.21(13), 3522–3533 (2007).
   PubMed Web of Science ®Google Scholar
• Ng CP, Hinz B, Swartz MA. Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro. J. Cell Sci.118(Pt 20), 4731–4739 (2005).
   PubMed Web of Science ®Google Scholar
• Ostberg JR, Kabingu E, Repasky EA. Thermal regulation of dendritic cell activation and migration from skin explants. Int. J. Hyperthermia19(5), 520–533 (2003).
   PubMed Web of Science ®Google Scholar
• Klas SD, Petrie CR, Warwood SJ et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine26(43), 5494–5502 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta RK. New advances in vaccine technologies and applications. 13–15 February 1995, Bethesda, Maryland, USA. Vaccine13(16), 1623–1625 (1995).
   Google Scholar
• Gupta RK, Siber GR. Adjuvants for human vaccines – current status, problems and future prospects. Vaccine13(14), 1263–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Alving CR, Detrick B, Richards RL, Lewis MG, Shafferman A, Eddy GA. Novel adjuvant strategies for experimental malaria and AIDS vaccines. Ann. NY Acad. Sci.690, 265–275 (1993).
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med.359(24), 2521–2532 (2008).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med.336(2), 86–91 (1997).
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-‘vaccinosis’: a dangerous liaison? J. Autoimmun.14(1), 1–10 (2000).
   PubMed Web of Science ®Google Scholar
• Waisbren BA Sr. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med. Hypotheses70(2), 346–348 (2008).
   PubMed Web of Science ®Google Scholar